黑色素瘤的生物标志物

doi:10.3760/cma.j.issn.1673-422X.2018.01.014

国际肿瘤学杂志 ›› 2018, Vol. 45 ›› Issue (1): 59-.doi: 10.3760/cma.j.issn.1673-422X.2018.01.014

黑色素瘤的生物标志物

王燕军，康晓静

830001 乌鲁木齐，新疆医科大学研究生学院；新疆维吾尔自治区人民医院皮肤性病科

出版日期:2018-01-08 发布日期:2018-02-12
通讯作者: 康晓静 E-mail:drkangxj666@163.com
基金资助:
新疆维吾尔自治区自然科学基金（2016D01C101）

Biomarkers for malignant melanoma

Wang Yanjun, Kang Xiaojing

Postgraduate School of Xinjiang Medical University; Department of Dermatology and Venereology, People′s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China

Online:2018-01-08 Published:2018-02-12
Contact: Kang Xiaojing E-mail:drkangxj666@163.com
Supported by:
Natural Science Foundation of Xinjiang Uygur Autonomous Region of China (2016D01C101)

摘要/Abstract

摘要： 黑色素瘤是一种侵袭性强的恶性肿瘤，其发病机制尚不清楚，这可能限制了黑色素瘤的研究及其生物标志物和治疗的发展。近年来，随着对黑色素瘤发病机制的深入研究和分子生物学技术的发展，发现一些新型生物标志物在黑色素瘤中发挥着重要作用。遗传和表观遗传因素是黑色素瘤发生和发展的重要原因，其中遗传基因突变是黑色素瘤重要的生物标志物，可为患者提供预后和个体化治疗的重要信息。表观遗传改变可作为诊断黑色素瘤的一种非侵入性手段，也可作为判断预后和预测疾病的新型生物标志物。黑色素瘤生物标志物的发现为疾病早期诊断、个体化治疗和判断预后提供了理论基础。

关键词: 黑色素瘤；遗传学；后成说, 遗传；生物学标记

Abstract: Malignant melanoma is one of the most aggressive cancers. The pathogenesis of melanoma has not been well documented, which may restrict the research and development of biomarkers and therapies. Recently, with the further study of the pathogenesis of melanoma and the development of molecular biology techniques, some new biomarkers have been found to play an important role in melanoma. Several genetic and epigenetic factors have been identified as contributing to the development and progression of melanoma. Considerable efforts have been made to classify melanoma into distinct subtypes based on genetic mutations and gene expression profile offer important information on patients′ prognosis and individual treatment options. Epigenetic alterations can be used as a noninvasive diagnostic tool for melanoma and can be used as a new biomarker for predicting prognosis and predicting disease. And the discovery of biomarkers for melanoma provides a theoretical basis for early diagnosis, individualized treatment and prognosis.

Key words: Melanoma, Genetics, Epigenesis, genetic, Biomarkers

王燕军，康晓静. 黑色素瘤的生物标志物[J]. 国际肿瘤学杂志, 2018, 45(1): 59-.

Wang Yanjun, Kang Xiaojing. Biomarkers for malignant melanoma[J]. Journal of International Oncology, 2018, 45(1): 59-.

参考文献

［1］ Sari Aslani F, Geramizadeh B, Dehghanian AR. Comparison of cKit expression between primary and metastatic melanoma of skin and mucosa［J］. Med J Islam Republic Iran, 2015, 29: 203. ［2］ Walesch SK, Richter AM, Helmbold P, et al. Claudin11 promoter hypermethylation is frequent in malignant melanoma of the skin, but uncommon in nevus cell nevi［J］. Cancers (Basel), 2015, 7(3): 12331243. DOI: 10.3390/cancers7030834. ［3］ Bruno W, Martinuzzi C, Andreotti V, et al. Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry［J］. Oncotarget, 2017, 8(5): 80698082. DOI: 10.18632/oncotarget.14094. ［4］ Greaves WO, Verma S, Patel KP, et al. Frequency and spectrum of BRAF mutations in a retrospective, singleinstitution study of 1112 cases of melanoma［J］. J Mol Diagn, 2013, 15(2): 220226. DOI: 10.1016/j.jmoldx.2012.10.002. ［5］ Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib［J］. N Engl J Med, 2015, 372(1): 3039. DOI: 10.1056/NEJMoa1412690. ［6］ Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAFmutated melanoma［J］. N Engl J Med, 2014, 371(20): 18671876. DOI: 10.1056/NEJMoa1408868. ［7］ Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a nonrandomised, openlabel phase 2 study［J］. Lancet Oncol, 2013, 14(3): 249256. DOI: 10.1016/S14702045(13)70024X. ［8］ Slipicevic A, Herlyn M. KIT in melanoma: many shades of gray［J］. J Invest Dermatol, 2015, 135(2): 337338. DOI: 10.1038/jid.2014.417. ［9］ Krauthammer M, Kong Y, Bacchiocchi A, et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sunexposed melanomas［J］. Nat Genet, 2015, 47(9): 9961002. DOI: 10.1038/ng.3361. ［10］ Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma［J］. Melanoma Res, 2014, 24(6): 525534. DOI: 10.1097/CMR.0000000000000121. ［11］ Ji ZY, Njauw CN, Taylor M, et al. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition［J］. J Invest Dermatol, 2012, 132(2): 356364. DOI: 10.1038/jid.2011.313. ［12］ Mazar J, Deblasio D, Govindarajan SS, et al. Epigenetic regulation of microRNA375 and its role in melanoma development in humans［J］. FEBS Lett, 2011, 585(15): 24672476. DOI: 10.1016/j.febslet.2011.06.025. ［13］ Friedman EB, Shang S, de Miera EV, et al. Serum microRNAs as biomarkers for recurrence in melanoma［J］. J Transl Med, 2012, 10(1): 155161. DOI: 10.1186/1479587610155. ［14］ Segura MF, Greenwald HS, Hanniford D, et al. MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy［J］. Carcinogenesis, 2012, 33(10): 18231832. DOI: 10.1093/carcin/bgs205. ［15］ Shiiyama R, Fukushima S, Jinnin MA, et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles［J］. Melanoma Res, 2013, 23(5): 366372. DOI: 10.1097/CMR.0b013e328363e485. ［16］ Tian R, Liu T, Qiao L, et al. Decreased serum microRNA206 level predicts unfavorable prognosis in patients with melanoma［J］. Int J Clin Exp Pathol, 2015, 8(3): 30973103. ［17］ Kostaki M, Manona AD, Stavraka I, et al. Highfrequency p16(INK) (4A) promoter methylation is associated with histone methyltransferase SETDB1expression in sporadic cutaneous melanoma［J］. Exp Dermatol, 2014, 23(5): 332338. DOI: 10.1111/exd.12398. ［18］ Lauss M, Ringner M, Karlsson A, et al. DNA methylation subgroups in melanoma are associated with proliferative and immunological processes［J］. BMC Med Genomics, 2015, 8: 73. DOI: 10.1186/s1292001501474. ［19］ Otsubo T, Hagiwara T, TamuraNakano M, et al. Aberrant DNA hypermethylation reduces the expression of the desmosomerelated molecule periplakin in esophageal squamous cell carcinoma［J］. Cancer Med, 2015, 4(3): 415425. DOI: 10.1002/cam4.369. ［20］ Micevic G, Theodosakis N, Taube JM, et al. Attenuation of genomewide 5methylcytosine level is an epigenetic feature of cutaneous malignantmelanomas［J］. Melanoma Res, 2017, 27(2): 8596. DOI: 10.1097/CMR.0000000000000315. ［21］ PerezRamirez C, CanadasGarre M, Angel Molina M, et al. PTEN and PI3K/AKT in nonsmallcell lung cancer［J］. Pharmacogenomics, 2015, 16(16): 18431862. DOI: 10.2217/pgs.15.122. ［22］ Roh MR, Gupta S, Park KH, et al. Promoter methylation of PTEN is a significant prognostic factor in melanoma survival［J］. J Invest Dermatol, 2016, 136(5): 10021011. DOI: 10.1016/j.jid.2016.01.024. ［23］ Hoshimoto S, Kuo CT, Chong KK, et al. AIM1 and LINE1 epigenetic aberrations in tumor and serum Relate to melanoma progression and disease outcome［J］. J Invest Dermatol, 2012, 132(6): 16891697. DOI: 10.1038/jid.2012.36.

黑色素瘤的生物标志物

Biomarkers for malignant melanoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价